Phases, active trials: Phase 1: 19, Phase 2: 33, Phase 3: 31, Other: 3
Gilead Sciences has evolved from a virology-focused company into a diversified biopharmaceutical with major oncology and liver disease programs. Their hematology-oncology franchise centers on CAR-T therapies, Yescarta (axicabtagene ciloleucel) for large B-cell lymphoma and follicular lymphoma, and Tecartus (brexucabtagene autoleucel) for mantle cell lymphoma and B-cell ALL. Through the acquisition of Immunomedics, Gilead gained Trodelvy (sacituzumab govitecan), a TROP2-targeting ADC approved in triple-negative breast cancer and urothelial cancer, with an active expansion program in HR+ breast cancer, NSCLC, and other solid tumors. In liver disease, Gilead's NASH/MASH pipeline includes seladelpar (PPARδ), cilofexor, and firsocostat across multiple combination trials. Their HIV franchise, anchored by Biktarvy and the lenacapavir long-acting program, continues generating registrations for pre-exposure prophylaxis and treatment extensions.
- Hematology / oncology (CAR-T, ADC)
- Solid tumors (TROP2, TROP2 combos)
- HIV (long-acting, PrEP, treatment)
- Liver disease (NASH/MASH, HCV/HBV)
- Inflammation (filgotinib, JAK1)
- Yescarta (axicabtagene ciloleucel): CD19 CAR-T, LBCL/FL
- Trodelvy (sacituzumab govitecan): TROP2 ADC, TNBC/urothelial
- Tecartus (brexucabtagene autoleucel): CD19 CAR-T, MCL/B-ALL
- Lenacapavir: HIV capsid inhibitor, long-acting
- Seladelpar: PPARδ agonist, MASH/PBC
- Magrolimab: CD47 antibody, myeloid malignancies
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 NCT06532656 | Primary completion moved at least 3 years 7 months later | Active, Not Recruiting |
10 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| Study of Sacituzumab Govitecan in Patients With Solid Tumor NCT05119907 | Oct 2026 · Estimated | Phase 2 |
7 more on the Completions page. See the calendar →
Monitor the Gilead Sciences pipeline daily
Get a daily digest when Gilead Sciences registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| HIV-1-infection | 11 |
| Pre-Exposure Prophylaxis of HIV Infection | 5 |
| Advanced Solid Tumors | 4 |
| HIV-1 Infection | 4 |
| Triple Negative Breast Cancer | 4 |
| Advanced Solid Tumor | 3 |
| HIV Infections | 3 |
| Non-small Cell Lung Cancer | 3 |
Gilead's Trodelvy (sacituzumab govitecan) expansion trials, into HR+ breast cancer, NSCLC, and endometrial cancer, are among the most competitive in the TROP2 ADC space, directly competing with AstraZeneca's Dato-DXd. Their lenacapavir long-acting HIV program is closely tracked for its pre-exposure prophylaxis indication registrations.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Gilead Sciences's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Gilead Sciences may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Gilead Sciences pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in… NCT07479797 | Recruiting | Trial sites expanded: 19 → 42 locations | 2026-10-09 |
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated… NCT06051617 | Recruiting | Trial sites expanded: 213 → 217 locations | 2026-10-07 |
| Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and… NCT06562907 | Recruiting | Completion pushed from Nov 2026 to Feb 2027 | 2026-10-07 |
| Study of Cell Therapies for the Treatment of Patients With Relapsed or… NCT05457010 | Active, Not Recruiting | Interventions modified | 2026-10-03 |
| Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in… NCT04150068 | Active, Not Recruiting | Completion pushed from Jan 2027 to Jan 2028 | 2026-10-02 |
Each trial page shows every change DataLookout has recorded for that trial.